Summary A prospective randomised study was carried out to compare the effect of mesna (2-mercaptoethane sulphonate sodium) with that of forced diuresis in preventing cyclophosphamide induced haemorrhagic cystitis in marrow transplant recipients. Sixty-one consecutive BMT recipients were randomised for treatment with forced diuresis or mesna. The incidence of macroscopic haematuria was significantly lower in the mesna treated group (X2 = 4.03, P <0.05). No specific side effects of mesna were detected. The lymphopenia induced by cyclophosphamide in the aplastic recipients was similar in the mesna and forced diuresis groups suggesting that mesna has no effect on the lymphocytotoxic activity of cyclophosphamide, although 6 out of 7 episodes of graft failure documented in the study occurred in mesna treated patients. As a result of this study our present policy is to use mesna in all BMT recipients but to continue careful documentation of the incidence of graft failure.
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High dose cyclophosphamide (HDC) is used as pregraft immunosuppression in bone marrow transplant recipients to prevent graft rejection. A total dose of 120-200mgkg-1 is given i.v. over 2-4 days either alone or in combination with total body irradiation (1000-1200cGy). Haemorrhagic cystitis is the most frequent serious side effect of HDC therapy in BMT recipients , this is thought to be caused by a metabolite of cyclophosphamide called acrolein (Cox et al., 1978) .
Forced diuresis with or without bladder irrigation has been used to prevent haemorrhagic cystitis by diluting the acrolein in the urine thereby reducing its contact with the urothelium. This procedure requires skilled supervision to prevent dangerous water overload and electrolyte imbalance particularly as HDC has an anti diuretic effect.
Mesna, (2-mercaptoethane sulphonate sodium), is a sulphydryl compound which has been developed to prevent haemorrhagic cystitis in patients receiving HDC or isophosphamide. It is administered i.v. and is rapidly excreted via the urinary tract. Within the urinary tract mesna combines with acrolein to form a non-toxic compound (Brock et al., 1979) . A preliminary study showed that only 1 out of 10 marrow transplant patients given HDC together with mesna developed haemorrhagic cystitis (Link et al., 1981 (Hows et al., 1983a, b 
Analysis of results
Three patients died within the study period, 2 in the mesna group and one in the forced diuresis group.
None of these patients had developed macroscopic haematuria at the time of death. The causes of death were cerebral haemorrhage (day + 15), cyclosporine toxicity (day +10) and acute GVHD (day + 14). As these patients were not studied for the full period they were excluded from the final analysis. Patients with microscopic haematuria had no symptoms or signs of cystitis and were therefore analysed with the patients completely free of haematuria.
Results
The incidence of haemorrhagic cystitis is shown in Table II infection (Table I) (Glucksberg et corrected for primary graft failure. In vitro mesna has no effect on the growth of normal marrow progenitor cells (Table IV) .
al., 1974). Numbers

Discussion
Haemorrhagic cystitis has been reported in -30% of BMT recipients receiving HDC despite prophylaxis with forced diuresis and bladder irrigation (Table II) . Administration of mesna was simple and required less nursing time than supervision of forced diuresis. Late onset haemorrhagic cystitis has been described during and following cyclophosphamide therapy (George, 1963 (Bryant et al., 1980) . Further studies have supported this finding showing that mesna is autooxidised in the plasma and therefore cannot affect active metabolites of cyclophosphamide or isophosphamide in the circulation (Brock et al., 1981) . In human marrow transplantation cyclophosphamide is used primarily for its immunosuppresive effect, rather than antitumour activity. In our study the aplastic recipients did not receive TBI so the immunosuppresive activity of HDC was of great importance for successful engraftment. It is notable that 6/7 of the episodes of graft failure occurring in the aplastic transplant recipients were in mesna treated patients (Table  III) . However, there was no difference in the lymphocytotoxic effect of cyclophosphamide as measured by the nadir of the lymphocyte count in forced diuresis and mesna treated patients. This finding makes it unlikely that mesna affects the lymphocytotoxic activity of cyclophosphamide. Mesna was administered the day before marrow infusion to the aplastic patients but not within 12h of the infusion. In one patient mesna was detected in the urine on the morning of the marrow infusion (data not shown). To exclude the possibility of a direct toxic effect of mesna on marrow progenitor cells GM-CFC cultures were carried out in the presence of supra pharmacological concentrations of the drug (Table IV) . From our in vitro results we conclude that mesna has no effect on GM-CFC and that direct toxicity to at least these marrow progenitor cells is an unlikely explanation for the high incidence of graft failure in the mesna treated aplastic patients.
In conclusion mesna is more effective than forced diuresis in preventing cyclophosphamide induced haemorrhagic cystitis in BMT recipients (P<0.05). However, treatment failures did occur possibly because there may be other causes of haemorrhagic cystitis than acrolein toxicity or the dose schedule of mesna was not optimal. Mesna was simpler to administer and required less supervision than forced diuresis. No immediate side effects of mesna were detected in this study nor could an effect of mesna on the lymphocytotoxic activity of cyclophosphamide be determined. The higher incidence of graft failure in the mesna treated aplastic patients compared to the forced diuresis group remains to be explained. As a result of this study our present policy is to use mesna to prevent haemorrhagic cystitis in all BMT recipients and to continue careful documentation of the incidence of graft failure in our patients.
